Krystal Biotech Q2 2026: Solid Growth, Strong Cash, But Revenue Shortfall Triggers Sell-Off
Krystal Biotech shares dropped after Q2 revenue missed forecasts, despite strong earnings, growth, and progress with VYJUVEK sales.
/ 2 items
Krystal Biotech shares dropped after Q2 revenue missed forecasts, despite strong earnings, growth, and progress with VYJUVEK sales.
Great news for DEB patients! VYJUVEK can now treat from birth and be applied at home by patients/caregivers. Plus, wound dressing changes are more flexible. These updates significantly improve convenience and quality of life, making it the standard treatment for all DEB wounds.